Foundation Fighting Blindness Retinal Degeneration Fund

FFB Retinal Degeneration Fund sold 1,700,000 shares (1.70M) of IRD at $4.35; stock now at $4.44, -23.6% from 52-week high.

Foundation Fighting Blindness Retinal Degeneration Fund, a director, divested 1,700,000 shares (1.70M shares) in a $7,395,000.00 sale at $4.35 on 2026-05-18, reducing holdings from 5,492,171 to 3,792,171 shares (-31.0% vs pre-transaction holdings). The sale occurs with the stock trading -23.6% from its 52-week high and having declined -19.9% over the prior 30 days, though it has gained +24.4% over 90 days. IRD is unprofitable, posting a net income of $-65,535,000.00 while generating only $2,157,000.00 in latest quarterly revenue, though annual revenue growth stands at +29.2%. The prior sale by this insider at this ticker (2025-12-09) delivered a 90-day return of +121.9%, a poorly-timed outcome relative to the insider's stated transaction pattern. The scale of this reduction—shedding nearly one-third of the existing position—paired with the company's significant losses and the stock's recent weakness merit investor attention to the timing and any accompanying disclosures around director positioning.

Director (Foundation Fighting Blindness) sold 4,000,000 shares at $2.15; exits 42.1% of stake from Opus Genetics unprofitable biotech.

Foundation Fighting Blindness Retinal Degeneration Fund (Director) divested 4,000,000 shares at $2.15 on 2025-12-09, reducing holdings from 9,492,171 shares to 5,492,171 shares—a 42.1% reduction in stake. This occurs in the context of deteriorating fundamentals: the company posted net income of $-17,454,000.00 for its most recent full fiscal year, quarterly revenue of $3,079,000.00, and year-over-year annual revenue decline of -42.3%. The sale price of $2.15 sits near the 52-week high of $2.50, and recent momentum (+76.8% over 90 days, +23.9% over 30 days) suggests the insider captured strength before the transaction. The material scale of the position reduction—eliminating nearly half the director's holdings—signals a structural shift in exposure to a loss-making enterprise facing significant revenue contraction.